Efficacy of Nisoldipine Compared with Nifedipine in Chronic Stable Angina Pectoris

  • H. Reicher-Reiss
  • Z. Vered
  • U. Goldbourt
  • H. N. Neufeld
Conference paper


The antianginal effects of the new calcium entry blocker nisoldipine were evaluated and compared with those of nifedipine in a double-blind study of two similar groups of 15 randomly allocated patients. Clinical assessment as well as submaximal ergometric exercise were performed before and after 4 and 8 weeks of continuing therapy with 10 mg nisoldipine daily or 10 mg nifedipine three times daily.

In a single patient study medication nisoldipine was discontinued due to the occurrence of marked tachycardia and increased incidence of chest pains. Other mild side effects occurred in three patients but did not necessitate discontinuation of the study.

The number of anginal attacks decreased from 5.5 to 1. 8 per week in the nisoldipine group and from 6.7 to 1.1 in the nifedipine group. The requirement for sublingual nitrates decreased accordingly. Exercise tolerance was significantly improved. Maximal workload (mean ± SE) increased during therapy from 67.0 ± 3.1 to 73.2 ± 4.0W (nisoldipine) and from 58.3 ± 6.5 to 65.0 ± 7.0 W (nifedipine).

Time to occurrence of chest pains during exercise increased from 9.0 ± 1.1 to 9. 75 ± 1.2 min and from 5.5 ± 0.5 to 7.5 ± 0.9 min (nifedipine).

At the last ergometry measurement during therapy, 4 of 14 patients on nisoldipine experienced chest pains on maximal exertion as compared with 6 on nifedipine.

Marked improvement was achieved in the ischemic ST depression at maximal exercise, as expressed in percent of baseline value, under both regimens. On nisoldipine therapy ST depression declined to 43.1% ± 9. 7% of baseline levels at the last ergometry reading. At the end nifedipine therapy the corresponding figure was 62.0% ± 15.2%. Time to occurrence of ST-segment depression was prolonged from 7.7 ± 0.8 to 8.6 ± 0.9 min (nisoldipine) and from 5.2 ± 0.7 to 6.4 ± 0.8 min (nifedipine).

Heart rate and blood pressure results during therapy were comparable in both groups. None of the trends over time were significantly different between the groups.

In conclusion appears that nisoldipine in the dosage used is at least as effective and well tolerated as nifedipine in its capacity as an antianginal agent.


Calcium Antagonist Maximal Exercise Chronic Stable Angina Anginal Attack Sublingual Nitroglycerin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Braunwald E (1982) Mechanism of action of calcium-channel blocking agents. N Engl J Med 307: 1618–1627PubMedCrossRefGoogle Scholar
  2. 2.
    Henry PD (1980) Comparative pharmacology of calcium antagonists: nifedipine, veraparnil, and diltiazem. Am J Cardiol 46: 1047–1057PubMedCrossRefGoogle Scholar
  3. 3.
    Theroux P, Taeymans Y, Waters DD (1983) Calcium antagonists: clinical use in the treatment of angina. Drugs 15: 178–195CrossRefGoogle Scholar
  4. 4.
    Leon MB, Rosing DR, Bonow RO, Lipson LC, Epstein SE (1981) Clinical efficacy ofverapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 48: 131–139PubMedCrossRefGoogle Scholar
  5. 5.
    Antman E, Muller JE, Goldberg S et al. (1980) Nifedipine therapy for coronary artery spasm: experience in 127 patients. N Engl J Med 302: 1269–1273PubMedCrossRefGoogle Scholar
  6. 6.
    Mueller HS, Chahine RA (1981) Interim report of multicenter double-blind placebo-controlled studies of nifedipine in chronic stable angina. Am J Med 71: 645–647PubMedCrossRefGoogle Scholar
  7. 7.
    Henry PD, Schuchleib R, Borda LJ, Roberts R, Williamson JR, Sobel BE (1978) Effects of nifedipine on myocardial perfusion and ischemic injury in dogs. Circ Res 43: 372–380PubMedGoogle Scholar
  8. 8.
    Kazda S, Garthoff B, Meyer H et al. (1980) Pharmacology of a new calcium antagonistic compound isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate (nisoldipine, Bay K 5552). Arzneimittelforsch 30: 2411–2462Google Scholar
  9. 9.
    Warltier DC, Meils CM, Gross GH, Brooks HL (1981) Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem, and nisoldipine (Bay K 5552), a new dihydropyridine calcium antagonist. J Pharmacol Exp Ther 218: 296–302PubMedGoogle Scholar
  10. 10.
    Vogt A, Neuholds KL, Krenzer H (1980) Hemodynamic effects of the new vasodilator drug Bay K 5552 in man. Arzneimittelforsch 30: 2162–2164PubMedGoogle Scholar
  11. 11.
    Lam J, Chaitman BR, Crean P, Blum R, Waters DD (1985) A dose-ranging, placebo-controlled double-blind trial of nisoldipine in effort angina: duration and extent of antianginal effects. J Am Coli Cardiol 6: 447–452CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • H. Reicher-Reiss
  • Z. Vered
  • U. Goldbourt
  • H. N. Neufeld

There are no affiliations available

Personalised recommendations